Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2012 Jun;26(6):1422-5.
doi: 10.1038/leu.2011.354. Epub 2011 Dec 16.

Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A

M S Spector, I Iossifov, A Kritharis, C He, J E Kolitz, S W Lowe, S L Allen
Case Reports

Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor β chain and KIT V654A

M S Spector et al. Leukemia. 2012 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Hemizygous deletion of chromosome 10q21.1 detected by high-resolution SNP array in leukemic cells and independent sequence confirmation for two non-synonymous somatic tumor variants. (a) The majority of chromosome 10 has 2N copy number (CN) and heterozygous B allele frequency (BAF), except for a hemizygous deletion (b) of chromosome 10q21.1; 2.6 Mb (chr10:54,305,820 – 56,908,099). This region encompasses one protein coding gene, PCDH15, and one microRNA gene, hsa-mir-548f-1. (c and d) Germline (saliva DNA) and tumor (leukemic) DNA were PCR amplified for (c) KIT (top two panels) and (d) MS4A2 (bottom two panels), and capillary sequenced. The germline genotype for KIT is homozygous T/T; GTG encodes for Valine 654. The tumor is heterozygous T/C; GCG encodes for Alanine. The germline genotype for MS4A2 is homozygous C/C; CTC encodes for Leucine 188. The tumor is heterozygous C/T; TTC encodes for Phenylalanine.
See this image and copyright information in PMC

References

    1. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006;6:218–230. - PubMed
    1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603–625. - PubMed
    1. Ustun C, Deremer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res. 2011;35:1143–1152. - PubMed
    1. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009;23:900–904. - PMC - PubMed
    1. Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011;96:459–463. - PMC - PubMed